Loading stock data…
ETON
$28.90+4.78 (+19.82%)
Market ClosedLast close May 1
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Eton Pharmaceuticals, Inc. in the Healthcare sector is trading at $28.90. The stock is currently near its 52-week high of $29.80, remaining 58.5% above its 200-day moving average. Technical signals show neutral RSI of 60 and bearish MACD signal, explaining why ETON maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 60) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$28.90
Potential Upside
5%
Whystock Fair Value$30.34
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$626.72M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.97
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-17.59%
Volume
Today's trading volume
960,038
Recent News
Eton Pharmaceuticals (ETON) Appoints Judith M. Matthews as New CFO
Eton Pharmaceuticals Inc. (NASDAQ:ETON) is one of the best NASDAQ growth stocks to buy and hold forever. On April 16, Eton Pharmaceuticals announced a succession plan for its Chief Financial Officer, appointing Judith M. Matthews as Executive Vice President of Accounting and Finance. Matthews is scheduled to officially assume the CFO role on June 1, […]
How The Hemangeol Deal Is Reframing The Eton Pharmaceuticals (ETON) Investment Story
Price targets on Eton Pharmaceuticals have been adjusted at the margins, with one bullish analyst moving from US$29 to US$30 while model fair value stays at US$39.33. That modest change is tied directly to commentary around the Hemangeol acquisition, where analysts weigh its US$12m in expected 2025 U.S. sales against execution risk and Eton's past licensing experience with Increlex. As you read on, you will see how these pieces fit together and what to watch to keep up with the evolving...
April 2026's Top Growth Companies With Strong Insider Ownership
Over the last 7 days, the United States market has risen by 3.1%, contributing to a substantial 27% climb over the past year, with earnings forecasted to grow by 16% annually. In such a robust market environment, growth companies with high insider ownership can be particularly attractive as they often indicate strong confidence from those closest to the business operations and future prospects.
How The Eton Pharmaceuticals (ETON) Story Is Shifting With Hemangeol And New Valuation Targets
Eton Pharmaceuticals is back in focus after an updated consolidated fair value estimate moved from US$30 to about US$39.33 per share. That shift sits at the center of current analyst debate, with bullish and bearish views largely hinging on how the Hemangeol acquisition and related execution risks compare with the new pricing framework. Read on to see what is driving the evolving story around these targets and how you can keep track as the narrative shifts. Analyst Price Targets don't always...
Tarsus Pharmaceuticals Stock Earns Upgrade To RS Rating
On Thursday, Tarsus Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 76 to 82. Looking For The Best Stocks To Buy And Watch? Start Here IBD's proprietary rating tracks share price performance with a 1 (worst) to 99 (best) score.